Physician profile

Alan Chalil

Neurological Surgery · Atlanta, GA

NPI 1013617687

$12,138.39

in general payments reported to CMS, 2019-2025

8 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Grant$6,750.00
Travel and Lodging$3,056.49
Food and Beverage$2,331.90

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbott Laboratories $6,750.00 2023
Neuropace, INC. $2,100.56 2023-2024
Zimmer Biomet Holdings, INC. $1,014.65 2024 Cep, Rosa
Dixi Medical USA Corp $980.82 2023
Boston Scientific Corporation $909.92 2024 Vercise
Stryker Corporation $175.07 2024 Insignia
Biotronik Nro, INC. $121.94 2024 Prospera
Clearpoint Neuro, INC. $85.43 2023 Clearpoint

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Alan Chalil

$12,138.39

in general payments reported 2019-2025

Years
2023-2024
Top company
Abbott Laboratories

https://glasscript.com/doctor/11455646/alan-chalil

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.